Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. **(Currently Amended)** A method of inhibiting the activity of a G1 cdk, comprising contacting said cdk with a substance ~~that includes~~ which is selected from the group consisting of a peptide fragment of 40 amino acids or less of p21, a derivative thereof, the peptide fragment or derivative thereof coupled to a non-peptidyl coupling partner and the peptide fragment or derivative thereof coupled to a non-p21 peptide sequence, the peptide fragment comprising the motif:

KxxRRyFzP

wherein

(a) x comprises any amino acid;

(b) y and z comprise hydrophobic amino acids;

(c) K is present, deleted or replaced by another amino acid; and

(d) P is present, deleted or replaced by another amino acid.

2. **(Previously Presented)** The method according to claim 1 wherein at least one of y or z comprises an amino acid selected from the group consisting of alanine, valine, leucine, isoleucine, proline, phenylalanine, tryptophan and methionine.

3. **(Currently Amended)** The method according to claim 1, wherein said substance consists of the peptide [[is a]] fragment of 40 amino acids or less of p21 or an active portion or derivative thereof.

4. **(Currently Amended)** The method according to claim 1, wherein said peptide fragment consists of residues 16-35 of the $p21^{WAF1}$ amino acid sequence or an active portion or derivative thereof.

5. **(Previously Presented)** The method according to claim 3 or 4, wherein said active portion or derivative has at least 80% identity over at least 5 amino acids of p21.

6. **(Currently Amended)** The method according to claim 1 wherein said substance is the peptide [[is]]fragment or derivative thereof coupled to a non-p21 peptide sequence~~carrier molecule~~.

7. **(Currently Amended)** The method according to claim 6, wherein the non-p21 peptide sequence~~carrier molecule~~ has the sequence RQIKIWFQNRRMKWKK.

8. **(Currently Amended)** The method according to claim 1 wherein the peptide fragment binds to a G1 cyclin or a G1 cdk.

9-10. **(Cancelled)**

11. **(Previously Presented)** The method according to claim 1 wherein the cdk activity comprises Rb phosphorylation.

12. **(Currently Amended)** The method according to claim 1 wherein ~~induction of~~ cell cycle arrest is induced~~tested~~.

13. **(New)** The method according to claim 1, wherein said substance is the peptide fragment or derivative thereof coupled to a non-peptidyl coupling partner.